このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

抗うつ薬療法に不十分な反応を示した不眠症症状を伴う大うつ病性障害の成人および高齢者の参加者における抗うつ薬の補助療法としてのセルトレキサントとクエチアピン XR との比較の研究

2026年11月11日 更新者:Janssen Research & Development, LLC

不眠症の症状を伴う大うつ病性障害を有する成人および高齢患者における抗うつ薬の補助療法としてのセルトレキサント 20 mg の有効性と安全性を評価するための比較対照としてクエチアピン持続放出を用いた二重盲検、無作為化、並行群間試験

The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

調査の概要

詳細な説明

Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.

研究の種類

介入

入学 (実際)

757

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • University of Alabama at Birmingham
    • Arizona
      • Tucson、Arizona、アメリカ、85712
        • SW Biomedical Research LLC
    • California
      • Culver City、California、アメリカ、90230
        • Proscience Research Group
      • Encino、California、アメリカ、91316
        • Pharmacology Research Institute
      • Garden Grove、California、アメリカ、92845
        • Collaborative NeuroScience Network
      • Long Beach、California、アメリカ、90806
        • Collaborative NeuroScience Network
      • Los Alamitos、California、アメリカ、90720
        • Pharmacology Research Institute
      • Los Angeles、California、アメリカ、90025
        • CalNeuro Research
      • Newport Beach、California、アメリカ、92660
        • Pharmacology Research Institute
      • Orange、California、アメリカ、92868
        • NRC Research Institute
      • Orange、California、アメリカ、92868
        • Pacific Neuropsychiatric Specialists
      • Pico Rivera、California、アメリカ、90660
        • CNRI-Los Angeles, LLC
      • Rancho Cucamonga、California、アメリカ、91730
        • Prospective Research Innovations Inc
      • Redlands、California、アメリカ、92374
        • Anderson Clinical Research
      • San Diego、California、アメリカ、92103
        • University of California at San Diego
      • Santa Ana、California、アメリカ、92705
        • CI Trials
      • Santa Ana、California、アメリカ、91704
        • National Research Institute
      • Santee、California、アメリカ、92071
        • CMB Clinical Trials
      • Sherman Oaks、California、アメリカ、91403
        • Schuster Medical Research Institute
      • Upland、California、アメリカ、91786
        • Pacific Clinical Research Medical Group
    • Connecticut
      • Hartford、Connecticut、アメリカ、06102
        • Hartford Hospital
    • Florida
      • Doral、Florida、アメリカ、33166
        • Moonshine Research Center, Inc
      • Hallandale、Florida、アメリカ、33009
        • Velocity Clinical Research, Hallandale Beach
      • Hialeah、Florida、アメリカ、33012
        • Indago Research & Health Center Inc
      • Hialeah、Florida、アメリカ、33012
        • New Life Medical Research Center, Inc.
      • Hialeah、Florida、アメリカ、33013
        • Amedica Research Institute Inc
      • Lakeland、Florida、アメリカ、33803
        • Meridien Research
      • Miami、Florida、アメリカ、33122
        • Premier Clinical Research
      • Miami、Florida、アメリカ、33125
        • Global Medical Institutes
      • Miami、Florida、アメリカ、33137
        • Miami Jewish Health System
      • Orlando、Florida、アメリカ、32806
        • Synexus Research Orlando
      • Orlando、Florida、アメリカ、23801
        • Clinical Neuroscience Solutions
      • Tampa、Florida、アメリカ、33612
        • University of South Florida
      • The Villages、Florida、アメリカ、32162
        • Compass Research LLC-Bioclinica Research
    • Georgia
      • Atlanta、Georgia、アメリカ、30331
        • Atlanta Center for Medical Research
      • Atlanta、Georgia、アメリカ、30328
        • Synexus Clinical Research US Inc
      • Decatur、Georgia、アメリカ、30030
        • iResearch Atlanta LLC
      • Marietta、Georgia、アメリカ、30060
        • Psych Atlanta, P.C.
    • Illinois
      • Chicago、Illinois、アメリカ、60634
        • Chicago Research Center
      • Libertyville、Illinois、アメリカ、60048
        • Capstone Clinical Research
      • Lisle、Illinois、アメリカ、60532
        • Alexian Brothers Health System
      • Naperville、Illinois、アメリカ、60563
        • Baber Research Group
      • Oakbrook Terrace、Illinois、アメリカ、60618
        • Lemah Creek Clinical Research
    • Kansas
      • Wichita、Kansas、アメリカ、67214
        • Ascension via Christi Research
    • Louisiana
      • New Orleans、Louisiana、アメリカ、70115
        • Riverstar Research
    • Maryland
      • Baltimore、Maryland、アメリカ、21208
        • Pharmasite Research, Inc.
    • Massachusetts
      • New Bedford、Massachusetts、アメリカ、02740
        • BTC of New Bedford
      • Roslindale、Massachusetts、アメリカ、02135
        • Boston Clinical Trials & Medical Research
    • Missouri
      • O'Fallon、Missouri、アメリカ、63368
        • Psychiatric Care and Research Center (PCRC)
    • New Jersey
      • Toms River、New Jersey、アメリカ、08755
        • Bio Behavioral Health
    • New York
      • Brooklyn、New York、アメリカ、11235
        • SPRI Clinical Trials, LLC
      • New York、New York、アメリカ、10128
        • The Medical Research Network, LLC
      • New York、New York、アメリカ、10017
        • Fieve Clinical Research Inc
      • Rochester、New York、アメリカ、14618 1609
        • Finger Lakes Clinical Research
      • Staten Island、New York、アメリカ、10312
        • Richmond Behavioral Associates
    • North Carolina
      • Durham、North Carolina、アメリカ、27701
        • Velocity Clinical Research, Inc.
    • Ohio
      • Cincinnati、Ohio、アメリカ、45219
        • University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
      • Dayton、Ohio、アメリカ、45417
        • Midwest Clinical Research Center
      • North Canton、Ohio、アメリカ、44720
        • Neuro Behavioral Clinical Research
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73112
        • Sooner Clinical Research
      • Oklahoma City、Oklahoma、アメリカ、73118
        • Paradigm Research Professionals, LLC
    • Pennsylvania
      • Pine Hill、Pennsylvania、アメリカ、08021
        • Suburban Research Associates
      • Scranton、Pennsylvania、アメリカ、18503
        • Global Medical Institutes
    • South Carolina
      • Mt. Pleasant、South Carolina、アメリカ、29464
        • Coastal Carolina Research Center
    • Texas
      • Bellaire、Texas、アメリカ、77401
        • West Houston Clinical Research Service
      • Fort Worth、Texas、アメリカ、76104
        • North Texas Clinical Trials
      • Mansfield、Texas、アメリカ、76054
        • Hawkins Psychiatry, PC
      • The Woodlands、Texas、アメリカ、77381
        • Family Psychiatry of The Woodlands
      • Wichita Falls、Texas、アメリカ、76309
        • Grayline Research Center
    • Utah
      • Clinton、Utah、アメリカ、84015
        • Alpine Research Organization
      • Draper、Utah、アメリカ、84020
        • Cedar Clinical Research
    • Virginia
      • Charlottesville、Virginia、アメリカ、22903
        • University of Virginia
    • Washington
      • Bellevue、Washington、アメリカ、98007
        • Northwest Clinical Research Center
      • Everett、Washington、アメリカ、98201
        • Core Clinical Research
    • Wisconsin
      • Waukesha、Wisconsin、アメリカ、53188
        • Cary J. Kohlenberg, MD, SC, dba, IPC Research.
      • Buenos Aires、アルゼンチン、1058AAJ
        • CENydET - Centro Neurobiologico y de Stress Traumatico
      • Buenos Aires、アルゼンチン、C1405BOA
        • FunDaMos
      • Buenos Aires、アルゼンチン、1199
        • Hospital Italiano
      • Ciudad Autonoma Buenos Aires、アルゼンチン、C1428AQK
        • Hospital Fleni
      • Córdoba、アルゼンチン、X5004AOA
        • Instituto Privado Kremer
      • Córdoba、アルゼンチン、5000
        • Fundacion Lennox
      • Córdoba、アルゼンチン、X5006IKK
        • Centro Medico Luquez
      • La Plata、アルゼンチン、Thanks
        • Clinica Privada de Salud Mental Santa Teresa de Ávila
      • La Plata、アルゼンチン、1902
        • CENPIA
      • Mendoza、アルゼンチン、M5502AWY
        • CENAIN
      • San Miguel de Tucumán、アルゼンチン、4000
        • Clinica Mayo de UMCB
      • Derby、イギリス、DE22 3LZ
        • Kingsway Hospital
      • Greater Manchester、イギリス、M15 6SX
        • Synexus
      • Harrogate、イギリス、HG1 2PW
        • Garden Valleys Resource Centre
      • London、イギリス、SE5 8EF
        • Kings College Hospital NHS Trust
      • Redruth、イギリス、TR15 2SP
        • Cornwall Partnership Foundation Trust
      • Hlevakha、ウクライナ、8631
        • MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
      • Kharkiv、ウクライナ、61068
        • Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
      • Kyiv、ウクライナ、04080
        • Kyiv Territorial Medical Incorporation 'Psychiatry'
      • Kyiv、ウクライナ、1030
        • Railway Clinical Hospital #1 of Kiev Railway station of DTGO 'South-Western Railway'
      • Kyiv、ウクライナ、1034
        • Medical Center Health and Happy
      • Nove、ウクライナ、25491
        • Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'
      • Ternopil、ウクライナ、46020
        • Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
      • Zaporizhzhya、ウクライナ、69600
        • Zaporizhzhia Regional Clinical Hospital
    • Nova Scotia
      • Sydney、Nova Scotia、カナダ、B1P 1E1
        • A.K. Munshi Medical Inc.
    • Ontario
      • Toronto、Ontario、カナダ、M3J 2C5
        • Canadian Phase Onward
    • Quebec
      • Montreal、Quebec、カナダ、H1M 1B1
        • Clinique Force Medic (GCP Trials)
      • Banská Bystrica、スロバキア、97401
        • Psychomed-Svatosavsky, s.r.o.
      • Bojnice、スロバキア、97201
        • Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
      • Košice、スロバキア、040 11
        • Epamed sro
      • Liptovský Mikuláš、スロバキア、03123
        • Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
      • Rimavská Sobota、スロバキア、97901
        • Psychiatricka Ambulancia Psycholine S.R.O.
      • Trenčín、スロバキア、91101
        • FN Trencin
      • Trenčín、スロバキア、91108
        • Pro mente sana s.r.o.
      • Žilina、スロバキア、1207
        • Fakultna nemocnica s poliklinikou v Ziline
      • Belgrade、セルビア、11000
        • University Clinical Center of Serbia
      • Belgrade、セルビア、11000
        • General Hospital Euromedik
      • Belgrade、セルビア、11000
        • University Clinical Hospital Center Dr Dragisa Misovic- Dedi
      • Belgrade、セルビア、11000
        • General Hospital Acibadem Bel Medic
      • Belgrade、セルビア、11000
        • Institute of Mental Health Serbia
      • Kovin、セルビア、26220
        • Special Neuropsychiatric Hospital Kovin
      • Kragujevac、セルビア、34000
        • University Clinical Center Kragujevac
      • Niš、セルビア、18000
        • Clinical Center Nis
      • Novi Kneževac、セルビア、23330
        • Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
      • Brno、チェコ、60200
        • Psychiatricka ambulance Saint Anne s.r.o.
      • Hradec Králové、チェコ、500 09
        • NeuropsychiatrieHK, s.r.o.
      • Pilsen、チェコ、301 00
        • A Shine S R O
      • Prague、チェコ、100 00
        • Clintrial s r o
      • Prague、チェコ、160 00
        • NeuropsychiatrieHK, s.r.o.
      • Prague、チェコ、10000
        • AD71 s.r.o.
      • Prague、チェコ、186 00
        • Institut Neuropsychiatricke pece
      • Pleven、ブルガリア、5800
        • Medical Center Medconsult-Pleven
      • Plovdiv、ブルガリア、4028
        • MC 'Hipokrat - N', EOOD
      • Rousse、ブルガリア、7003
        • Mental Health Center - Rousse
      • Sofia、ブルガリア、1680
        • Medical Center Intermedica, OOD
      • Sofia、ブルガリア、1113
        • Medical Center St. Naum
      • Sofia、ブルガリア、1784
        • MC 'Synexus Sofia' EOOD
      • Stara Zagora、ブルガリア、6003
        • UMHAT Prof. Dr. St. Kirkovich AD
      • Stara Zagora、ブルガリア、6000
        • MC 'Synexus Sofia' EOOD
      • Tzarev Brod、ブルガリア、9747
        • State Psychiatric Hospital - Tzarev Brod
      • Varna、ブルガリア、9020
        • Diagnostic Consulting Center Mladost - M Varna
      • Veliko Tarnovo、ブルガリア、5000
        • Mental Health Center - Veliko Tarnovo EOOD
      • Bruges、ベルギー、8310
        • AZ Sint-Lucas
      • Sint-Niklaas、ベルギー、9100
        • AZ Nikolaas
      • Bełchatów、ポーランド、97-400
        • Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
      • Bialystok、ポーランド、15-464
        • Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
      • Bydgoszcz、ポーランド、85-080
        • Przychodnia Srodmiescie SP. z o.o.
      • Gdansk、ポーランド、80 546
        • Centrum Badan Klinicznych PI House sp z o o
      • Lodz、ポーランド、90-009
        • Specjalistyczna Indywidualna Praktyka Lekarska
      • Lodz、ポーランド、90-368
        • CCBR - Lodz - PL
      • Lublin、ポーランド、20-582
        • Specjalistyczna Praktyka Lekarska Marek Domanski
      • Poznan、ポーランド、60-702
        • Synexus Polska Sp. z.o.o. Oddzial w Poznaniu
      • Warsaw、ポーランド、01 737
        • Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp z o.o.
      • Warsaw、ポーランド、02 957
        • Instytut Psychiatrii I Neurologii
      • Ipoh、マレーシア、30990
        • Hospital Raja Permaisuri Bainun
      • Johor Bahru、マレーシア、81200
        • Hospital Permai
      • Pulau Pinang、マレーシア、10990
        • Hospital Pulau Pinang
      • Seremban、マレーシア、70300
        • Hospital Tuanku Jaafar
      • Jelgava、ラトビア、LV-3008
        • The Mental Hospital of Jelgava Ģintermuiža - Psychiatry
      • Liepāja、ラトビア、LV-3401
        • L. Keruze Practice in Psychiatry
      • Outpatient Centre of Psychiatry、ラトビア、LV-4601
        • Hospital of Rezekne
      • Riga、ラトビア、LV-1002
        • Riga Centre of Psychiatry and Narcology
      • Kaunas、リトアニア、48259
        • Kaunas Silainiu Outpatient Clinic, Public Institution
      • Kaunas、リトアニア、53136
        • Republic Kaunas Hospital
      • Kaunas、リトアニア、LT-44279
        • Romuvos Klinika, JSC
      • Kaunas、リトアニア、LT-50009
        • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
      • Vilnius、リトアニア、09112
        • Zirmunai Mental Health Center, Public Institution
      • Vilnius、リトアニア、10309
        • Vilnius Mental Health Center
      • Vilnius、リトアニア、10204
        • Antakalnis Psychiatric Consultation Centre, Public Institution
      • Šilutė、リトアニア、99176
        • Medical Center Puriena JSC
      • Engel's、ロシア、413124
        • Engels psychiatric hospital
      • Kemerovo、ロシア、650036
        • Kemerovo Regional Clinical Psychiatric Hospital
      • Lipetsk Region、ロシア、399313
        • GUZ Lipetsk Regional psychoneurological Hospital #1
      • Moscow、ロシア、105082
        • JSC Scientific Centre of Personalized Medicine
      • Moscow、ロシア、107076
        • FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia
      • Moscow、ロシア、107076
        • Moscow Scientific Research Institute of Psychiatry
      • Omsk、ロシア、644070
        • Clinical Psychiatry Hospital n.a. N.N. Solodovnikov
      • Saint Petersburg、ロシア、192019
        • St-Petersburg Bekhterev Psychoneurological Research Institute
      • Tomsk、ロシア、634009
        • Klinika StoLet Ltd
      • Yekaterinburg、ロシア、620030
        • Sverdlov Regional Psychiatric Clinical Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~74年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (<=) 24 months
  • Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms present other than insomnia, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
  • Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
  • Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a clinically significant improvement (that is, an improvement of > 20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >18 at the second screening interview
  • Have a patient version insomnia severity index (ISI) total score >= 15 as well as a clinician version of the ISI total score >= 15 at the second screening visit
  • Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2), inclusive (BMI=weight/height^2)
  • Participant must be medically stable on the basis of the following: physical examination, vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline

Exclusion Criteria:

  • Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency (creatinine clearance [CrCl] less than [<] 30 milliliter per minute [mL/min]); clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
  • Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
  • Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders
  • Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
  • Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Seltorexant

Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.

Participants will receive seltorexant over-encapsulated tablet orally.

Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.

アクティブコンパレータ:Quetiapine Extended-Release (XR)

Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.

Participants will receive quetiapine XR capsule orally.

Participants will receive placebo capsule matching to quetiapine XR orally.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
時間枠:Week 26

Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with >= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26

二次結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline to Week 26 in Weight
時間枠:Baseline (Day 1) and Week 26

Change from baseline to Week 26 in weight was reported.

Baseline (Day 1) and Week 26
Time to Potentially Treatment Related Discontinuation of Study Drug
時間枠:From first dose of study drug (Day 1) up to Week 30

Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used.

From first dose of study drug (Day 1) up to Week 30
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
時間枠:Baseline (Day 1) and Week 26

Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in MADRS-6 Total Score
時間枠:Baseline (Day 1) and Week 26

Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
時間枠:Baseline (Day 1) and Week 26

The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
時間枠:Baseline (Day 1) and Week 26

Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement.

Baseline (Day 1) and Week 26
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
時間枠:Week 26

Percentage of participants with MADRS total score <=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was <=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
時間枠:Week 26

Percentage of participants with a >=50 percent improvement in MADRS total score and MADRS <=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
時間枠:Week 26

Percentage of participants with >=7 percent weight increase from baseline at Week 26 was reported.

Week 26

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年9月15日

一次修了 (実際)

2023年10月3日

研究の完了 (実際)

2023年10月3日

試験登録日

最初に提出

2020年8月13日

QC基準を満たした最初の提出物

2020年8月13日

最初の投稿 (実際)

2020年8月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CR108810
  • 42847922MDD3005 (その他の識別子:Janssen Research & Development, LLC)
  • 2020-000341-14 (EudraCT番号)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する